ROBOSENSE
2.3.2023 15:06:52 CET | Business Wire | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, has announced the launch of its first automotive-grade solid-state LiDAR perception solution for L4 autonomous driving, the RS-Fusion-P6 (P6). With advanced software and hardware support from RoboSense, the P6 provides precise and intelligent environmental perception capabilities, enabling autonomous vehicles to navigate through complex driving scenarios with ease, helping to reduce costs and increase efficiency, and promoting the rapid implementation of large-scale autonomous driving commercial operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005545/en/
RS-Fusion-P6 (Photo: Business Wire)
As an automotive-grade solid-state LiDAR perception solution, the P6 perfectly integrates hardware based on two-dimensional MEMS scanning technology and software based on artificial intelligence technology, fully demonstrating the leading level of RoboSense's core technologies in the areas of chips, hardware, and software.
RoboSense's RS-Fusion-P6 solution is designed to be flexible and scalable, making it suitable for a wide range of autonomous driving applications. It can be customized to meet the specific needs of different vehicle platforms and applications, providing a high level of performance and accuracy for all types of autonomous driving scenarios.
The P6 offers high-performance perception capabilities for full-scene environments from start to finish, making it ideal for a range of driving scenarios, including city streets, highways, and everything in between. Equipped with the four M-series solid-state LiDARs, the P6 offers dynamic switching and high-resolution long-distance detection capabilities, enabling intelligent perception over a 360-degree horizontal range, and allowing it to detect traffic conditions up to 200 meters away. The P6 can quickly process this data and provide feedback to the autonomous driving control center, allowing the vehicle to react in milliseconds to any changes in the driving environment.
P6 is equipped with RoboSense self-developed real-time point cloud perception software Perception. Under the intelligent processing of perception, P6 will be able to accurately process complex traffic environment information. Even in challenging driving scenarios, such as mixed traffic and inclement weather conditions, the P6 can accurately identify pedestrians, electric vehicles, cars, trucks, and other obstacles while tracking their speed, acceleration, and location. With this precise environmental perception data, autonomous vehicles equipped with the P6 can make accurate judgments and perform corresponding actions in real-time.
The launch of the P6 demonstrates RoboSense's deep understanding of the pain points in the autonomous driving industry. As the automotive industry continues to rapidly evolve, the P6 provides a reliable and high-performance perception solution that can help to accelerate the adoption of autonomous driving technology. With the P6, RoboSense further expands its product portfolio, which includes mechanical and solid-state LiDAR sensors, perception software, and integrated sensing solutions.
With its advanced perception capabilities and robust product portfolio, RoboSense is well-positioned to help accelerate the adoption of autonomous driving technology across a range of industries, including transportation, logistics, and mobility.
Full article of P6 in detail: https://www.robosense.ai/en/news-show-1690
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005545/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom